When Drug Labels Aren’t Enough: The Federal Circuit’s Ruling in Corcept Therapeutics v. Teva
When Drug Labels Aren’t Enough: The Federal Circuit’s Ruling in Corcept Therapeutics v. Teva
Patent litigation between brand-name drug manufacturers and generic competitors often hinges on a deceptively simple question: will physicians actually practice the patented method if the generic product enters the market?
The decision in Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. illustrates how courts answer that question in the context of Hatch-Waxman Act litigation. In February 2026, the U.S. Court of Appeals for the Federal Circuit affirmed a district court ruling holding that Teva did not induce infringement of Corcept’s method patents, even though Teva’s generic drug label referenced dosing instructions similar to the patented method.
The decision reinforced a critical principle in pharmaceutical patent law: a drug label that appears to recommend an infringing use is not always enough to establish infringement. Courts may look outside the label to determine whether physicians will actually perform the patented method.
This ruling has significant implications for:
Brand pharmaceutical companies relying on method-of-treatment patents
Generic drug manufacturers defending against infringement claims
Investors and analysts evaluating the strength of drug exclusivity strategies
In short, Corcept v. Teva adds another important chapter to the evolving law governing induced infringement.
The Regulatory and Legal Background: Understanding Hatch-Waxman Litigation
To understand the dispute, it helps to understand how pharmaceutical patent disputes typically arise. Generic drug manufacturers seeking approval from the U.S. Food and Drug Administration typically file an Abbreviated New Drug Application (ANDA). This allows the company to rely on the safety and efficacy data from the branded drug while proving bioequivalence.
When filing an ANDA, the generic manufacturer must certify the status of patents listed in the FDA’s Orange Book. One of the most common paths is a Paragraph IV certification, where the generic company claims that the branded drug’s patent:
Is invalid
Is unenforceable
Will not be infringed by the generic drug
Filing such a certification constitutes an “artificial act of infringement” under 35 U.S.C. § 271(e)(2), allowing the patent holder to file suit before the generic drug reaches the market.
Method-of-Treatment Patents
Many pharmaceutical patents claim methods of using a drug, rather than the drug compound itself. Examples include methods that involve:
Administering the drug with another medication
Using a specific dosing range
Treating a particular patient population
For these patents, infringement usually occurs when a physician performs the claimed method, not when the drug is manufactured or sold. That creates a complication in Hatch-Waxman litigation: generic manufacturers are typically accused of inducing physicians to infringe through drug labeling.
The Drug and Patents at the Center of the Dispute
The dispute involved the drug Korlym, marketed by Corcept Therapeutics. Korlym contains mifepristone, which is used to treat Cushing's syndrome, a disorder caused by excessive cortisol levels.
Corcept asserted two patents covering methods of safely administering mifepristone with strong CYP3A inhibitors. The patented methods addressed the risk of drug interactions by adjusting dosing when the drugs were co-administered. These patents were intended to protect clinical guidance on combining the medications safely.
Generic manufacturer Teva Pharmaceuticals USA sought FDA approval to market a generic version of Korlym. Importantly, Teva’s proposed label closely mirrored Corcept’s own drug label, including information about dosing adjustments when strong CYP3A inhibitors are involved. At first glance, this looked like a straightforward infringement case, but the courts ultimately saw it differently.
The Core Legal Issue: Can a Drug Label Alone Prove Infringement?
The central question before the court was whether Teva’s label would induce physicians to practice Corcept’s patented methods. In many Hatch-Waxman cases, labels play a decisive role. Courts often examine whether the label:
Encourages physicians to perform the patented method
Recommends the infringing use
Provides instructions that necessarily lead to infringement
However, the Federal Circuit has increasingly recognized that labels do not always dictate physician behavior. This principle traces back to earlier precedent, including Genentech, Inc. v. Sandoz Inc. That case held that even a label recommending an infringing use may be insufficient if real-world evidence shows physicians would not actually follow that method. The same reasoning became central in Corcept v. Teva.
What the District Court Found
The initial case was heard in the U.S. District Court for the District of New Jersey. After evaluating the evidence, the court concluded that Corcept failed to prove direct infringement. This determination rested on several key findings.
1. No Evidence of Past Infringement: One of the most striking facts in the case was that Corcept presented no evidence that any physician had ever practiced the patented method. Given that the drug had been on the market for years, the absence of such evidence was significant.
2. Physicians Avoid the Claimed Method: Clinical testimony showed that doctors generally avoid co-administering mifepristone with strong CYP3A inhibitors because of: 1) Safety concerns, 2) Complicated dosing adjustments, and 3) Risk of adverse interactions
3. Non-Infringing Alternatives Were Available: Physicians had access to other treatments that were not covered by the patented method. One example involved the use of Osilodrostat, which is a prescription drug that blocks cortisol production and avoids the interaction issues entirely.
4. The Label Did Not Require Infringement: The court also concluded that a physician could follow Teva’s label without performing the patented method. The label described dosing adjustments only if the physician chose to co-administer the drugs, leaving non-infringing options available. Taken together, the district court found that future infringement was unlikely.
The Federal Circuit’s Decision and Key Legal Principles
On appeal, the U.S. Court of Appeals for the Federal Circuit affirmed the district court’s ruling that Teva’s proposed generic product did not infringe Corcept’s asserted method-of-treatment patents. The appellate court agreed that Corcept failed to prove that physicians would likely perform the patented method if Teva’s generic drug entered the market.
A central theme in the decision was that courts are not limited to the wording of a drug label when evaluating infringement in Hatch-Waxman litigation. Even if a label references the patented method, courts may examine real-world evidence to determine whether physicians would actually perform the claimed steps. That evidence can include physician testimony, medical guidelines, clinical practice patterns, and the availability of alternative treatments. In this case, the record suggested that doctors generally avoided the specific co-administration scenario described in the patents, making future infringement unlikely.
The Federal Circuit also emphasized that the burden of proof remains on the patent holder in ANDA litigation. A brand-name manufacturer must show that infringement will likely occur if the generic drug is approved and marketed. Corcept could not meet that burden, in part because it could not identify evidence that physicians had previously practiced the patented method despite years of Korlym being on the market.
Finally, the court reiterated an important doctrinal point about induced infringement. Under the Supreme Court’s decision in Limelight Networks, Inc. v. Akamai Technologies, Inc., induced infringement requires proof that someone will directly infringe the patent. If physicians are unlikely to perform the patented method, then a generic manufacturer cannot be liable for inducing infringement through its labeling. Because the evidence suggested that the claimed treatment protocol was rarely, if ever, used in practice, the Federal Circuit concluded that Teva’s label would not induce infringement.
Broader Implications and Practical Takeaways for Pharmaceutical Companies
The decision in Corcept v. Teva carries important implications for pharmaceutical patent strategy, particularly for companies relying on method-of-treatment patents. Historically, many Hatch-Waxman cases focused heavily on the language of the generic drug’s label. If the label recommended the patented method, courts often treated that as strong evidence of inducement. The Federal Circuit’s analysis here reinforces that label language alone may not be sufficient. Courts may also consider how physicians actually prescribe medications in real clinical settings.
This shift can make certain types of patents more difficult to enforce. Method-of-treatment patents that depend on uncommon dosing adjustments, complicated drug interactions, or treatment protocols that physicians tend to avoid may face additional scrutiny. If doctors rarely follow the patented method, or if alternative therapies are widely available, patent owners may struggle to show that infringement will likely occur.
For pharmaceutical companies, the case highlights the growing importance of real-world medical evidence in Hatch-Waxman disputes. Evidence about clinical practice may now play a decisive role in determining whether inducement can be proven.
Brand-name manufacturers should consider documenting how physicians use their products in practice. Evidence showing that doctors routinely follow the patented treatment protocol can strengthen inducement claims. Companies may also benefit from drafting method claims that align closely with standard clinical practice and from developing broader patent portfolios that include formulation, dosing, or drug-delivery innovations.
Generic manufacturers, by contrast, may use evidence of prescribing behavior to demonstrate that infringement is unlikely. Testimony from physicians, medical literature, and treatment guidelines can help show that the patented method is rarely used or discouraged in practice. Generic companies may also emphasize that their proposed label allows physicians to prescribe the drug in non-infringing ways.
Ultimately, Corcept v. Teva underscores a broader reality in pharmaceutical patent litigation: courts increasingly look beyond the text of a drug label to evaluate how medicines are actually used in clinical practice. For companies navigating Hatch-Waxman disputes, successful litigation strategies will likely require both careful legal analysis and a clear understanding of real-world medical decision-making.
If you’re interested in learning more about this topic or how the principles discussed in this article may impact your business, don’t hesitate to contact us at info@patentxl.com or at +1(610)871-2024.
